Form 4: Arvinas Director Linda Bain Receives Significant Equity Awards

Arvinas, Inc. Director Linda Bain was granted 16,025 restricted stock units and 23,105 stock options as part of her compensation, aligning her interests with shareholders.

Summary

• Linda Bain, a Director of Arvinas, Inc. (ARVN), reported the acquisition of equity awards on June 25, 2025.
• She was granted 16,025 shares of common stock in the form of Restricted Stock Units (RSUs) at an acquisition price of $0.
• These RSUs represent a contingent right to receive one share of common stock per unit upon settlement and will vest in full on the earlier of June 25, 2026, or the first board meeting after the next annual stockholders meeting, subject to continued service.
• Additionally, Ms. Bain received 23,105 stock options with an exercise price of $7.8 per share.
• These stock options also vest in full on the earlier of June 25, 2026, or the first board meeting after the next annual stockholders meeting, subject to continued service, and have an expiration date of June 24, 2035.
• Following these transactions, Ms. Bain beneficially owns 26,045 shares of common stock and 23,105 derivative stock options directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation filing, indicating standard corporate governance practices and aligning director interests with shareholders, which is generally viewed favorably.

Positives

• The granting of equity awards to a director, Linda Bain, aligns her financial interests directly with those of the company's shareholders, encouraging long-term value creation.
• The awards are subject to vesting conditions tied to continued service, promoting stability in board leadership.

Risks

• None directly mentioned in this transaction report, as Form 4 filings primarily detail insider trading activities and compensation awards, not company-specific risks.

Future Outlook

The document indicates that the granted Restricted Stock Units and Stock Options will vest on the earlier of June 25, 2026, or the first meeting of the board of directors held after the next annual meeting of stockholders, contingent upon Linda Bain's continued service with Arvinas, Inc.

Industry Context

This Form 4 filing details a routine equity compensation grant to a director, which is a common practice across publicly traded companies in the biotechnology and pharmaceutical sectors, including Arvinas, Inc. Such grants are designed to incentivize long-term performance and align management and board interests with shareholder value.

Comparison to Industry Standards

• The granting of Restricted Stock Units (RSUs) and stock options as part of director compensation is a standard practice across various industries, including biotechnology, to attract and retain qualified board members.
• The vesting schedule, typically tied to continued service over one to three years, is also common for such awards, ensuring alignment with long-term company performance.
• While specific comparable companies or projects are not detailed in this Form 4, the structure of these equity awards is consistent with compensation practices observed at peer companies within the biopharmaceutical industry.

Corporate Governance

Related Party Transactions

• The equity awards granted to Linda Bain, a director of Arvinas, Inc., constitute a related party transaction as they involve compensation from the company to a member of its board of directors. This is a standard and disclosed form of related party dealing for executive and director compensation.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholders, potentially leading to better long-term performance and value creation.
• Employees: No direct impact on general employees is indicated by this filing.
• Management: The awards are part of the compensation structure for the board, which oversees management, reinforcing governance alignment.

Next Steps

• Continued service of Linda Bain with Arvinas, Inc. to fulfill vesting conditions for the equity awards.
• Vesting of Restricted Stock Units and Stock Options on or after June 25, 2026, or the first board meeting after the next annual stockholders meeting.

Key Dates

Keywords

Arvinas, ARVN, Form 4, Insider Transaction, Equity Award, Restricted Stock Units, Stock Options, Director Compensation, Corporate Governance